Amplify Weight Loss Drug & Treatment ETF THNR
25.65 USD -0.28 (-1.07%)
Nov 3, 2026, 1:59 PM EST
25.65 Day range 25.65
23.16 52-week range 27.94
- YTD
- +1.69%
- 1 year
- +10.40%
- Market cap
- 5.96M
- EPS (ttm)
- 1.22
- P/E ratio
- 21.04
- YTD return
- +1.69%
- 1-year return
- +10.40%
- Volume
- 175
- Avg volume
- 1.24K
- Open
- 25.79
- Previous close
- 25.92
- Day's range
- 25.65 – 25.65
- 52-week range
- 23.16 – 27.94
2Y +0.73 (+2.90%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 24.63
- 200-day average
- 25.88
About Amplify Weight Loss Drug & Treatment ETF
The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. GLP-1 agonists seek to lower blood sugar levels and reduce appetite and promote fullness, with the ultimate potential for weight loss. The fund is non-diversified.
News
What the Holidays Hold for GLP-1 Stocks in THNR 
Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss 
Bet on This New GLP-1 ETF to Gain Exposure to a Booming Market 
From Laggard to Leader: The Surprising Comeback of Healthcare 
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win 
Who Are You Calling Passive? Many Index ETFs Dynamically Rebalanced in September 
NTHM's Index Rebalance Puts Thematic Rotation to Work 
THNR's Weight-Loss Index Swaps Hims & Hers for Gilead 
Inside THNR: A Leaner Approach to Weight Loss Investing 
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
Your note
Sign in to keep a note on THNR — it syncs with the Stock Master app.